Actively Recruiting
Study of Safety, Tolerability, and Effects of NNC0721-8060 Compared to Semaglutide and Placebo in Adults with Overweight or Obesity
Led by Novo Nordisk A/S · Updated on 2026-09-04
142
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and how the new drug NNC0721-8060 works in adults living with overweight or obesity. This phase 1 study includes participants aged 18 to 55 years with a body mass index BMI between 27.0 and 34.9 kgm. The study compares NNC0721-8060 to semaglutide and a placebo, all given by subcutaneous injection. Participants will be randomly assigned to receive subcutaneous injections of NNC0721-8060, semaglutide, or placebo. The study includes multiple parts lasting from 36 to 113 days, during which the effects and safety of the treatments will be monitored closely. During the study, participants will undergo medical exams, vital sign checks, electrocardiograms, and laboratory tests. Researchers will track treatment-emergent adverse events and changes in body weight over time. The study also measures how the drug moves through and affects the body. Participants health and safety will be monitored throughout, with the total study duration depending on the treatment part they are assigned to.
CONDITIONS
Brief Title
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
